AOD-9604 peptide: what the human trial data actually shows

Last updated 2026-07-25

What is AOD-9604 peptide, exactly?

AOD-9604 is a synthetic fragment of human growth hormone, specifically the C-terminal region (amino acids 176-191) that researchers identified as the part responsible for HGH's fat-metabolizing effect. The idea, going back to work in the late 1990s and early 2000s, was to isolate just that fat-burning piece and leave behind the parts of HGH that drive tissue growth, insulin resistance, and the other side effects that make full-length growth hormone a complicated drug to use for weight loss. The company that developed it, Metabolic Pharmaceuticals (later Phosphagenics), pushed it through a clinical development program aimed squarely at obesity. A 2004 paper in Current Opinion in Investigational Drugs lays out the metabolic rationale: the fragment was designed to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without the growth-promoting or blood-sugar effects of the full hormone ^[1]. That's the pitch you still see repeated across peptide forums and vendor sites today: "the fat-burning part of HGH, without the side effects." It's a real hypothesis, not a coined-up gimmick, and it was tested. That's actually the more useful and more sobering part of the story, because it means we're not guessing. There's a real trial record. It just doesn't say what most of the marketing implies. If you're comparing AOD-9604 peptide against other fragment or growth-hormone-adjacent compounds, it helps to see how it stacks up specifically against something like tesamorelin, which does have FDA approval for a narrow indication. See AOD-9604 vs tesamorelin for that comparison.

Did AOD-9604 pass human obesity trials?

AOD-9604 went through human trials for obesity, and this is the central fact anyone researching it needs to sit with: the weight-loss results did not separate convincingly from placebo. Phase II work reportedly showed some effect, but the compound never reached the point of generating a regulatory approval anywhere, and no company has since revived it as an obesity drug. The broader trial infrastructure that supported peptide obesity candidates in the mid-2000s is documented in a 2006 review of obesity drugs in clinical development, which situates AOD-9604 among a wave of compounds being tested for weight management around that period ^[2]. That review is a survey of the pipeline, not a trial report itself, but it confirms AOD-9604 was a live obesity candidate being tracked alongside other mechanisms at the time. What you won't find, searching the primary literature, is a large randomized controlled trial with a clean, statistically separated weight-loss endpoint that beat placebo by a clinically meaningful margin and got published in a flagship journal. That's a real gap. When a peptide has genuinely strong human obesity data, it tends to show up as an FDA submission, not as a compounding pharmacy product. AOD-9604 never got there. This doesn't mean the fragment does nothing in a petri dish or in animal models. It means the leap from "plausible mechanism" to "reliable human fat loss" did not hold up when it was actually tested in people at the scale needed to prove it. That gap between mechanism and outcome is the single most important thing to understand before spending money on this peptide.

How does AOD-9604 supposedly cause fat loss?

The mechanism, as originally proposed, ties back to the specific fragment of HGH the peptide mimics. The C-terminal fragment (176-191) of human growth hormone was identified as retaining the lipolytic activity of the whole molecule, meaning it should, in theory, encourage the body to release and burn stored fat, particularly in a way that doesn't require the growth-hormone-receptor-mediated effects that drive height and organ growth ^[1]. In cell and animal studies, this fragment showed activity consistent with that hypothesis: stimulating fat cell breakdown and blunting new fat storage. That's a legitimate finding worth citing, and it's the reason AOD-9604 got funded into human trials in the first place. Nobody invests in a phase II obesity program on a whim. The honest caveat is that a mechanism working in isolated fat cells or in rodents frequently does not translate into a measurable, reliable effect in free-living humans eating real food and moving through a real day. That's true of dozens of obesity compounds that never made it past phase II. AOD-9604 is one example among many where the cell biology looked promising and the human efficacy data didn't confirm it at a level regulators or serious researchers found convincing.

Is AOD-9604 approved by the FDA for fat loss or anything else?

No. AOD-9604 does not appear in the FDA's Drugs@FDA database as an approved product for any indication, which you can verify directly by searching the agency's own database of approved drug products ^[3]. There is no FDA-approved use for AOD-9604, for obesity, injury recovery, or anything else. That matters for a second reason beyond simple approval status: the FDA maintains lists under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act that define which bulk drug substances compounding pharmacies may legally use. AOD-9604 is not on the 503A bulks list ^[4] or the 503B bulks list ^[5], and it's also not on the FDA's current list of substances nominated for compounding consideration that have been evaluated ^[6]. Pharmacy compounding itself is authorized under 21 U.S.C. 353a ^[7], but that authorization only covers substances that meet the statute's criteria, and AOD-9604 sits outside the approved bulks framework as of this writing. Practically, this means AOD-9604 products in the US market exist in a research-use gray zone. Anything labeled or sold implying a therapeutic or cosmetic use for a human runs into the FDA's own definition of "intended use" under 21 CFR 201.128, which looks at labeling, advertising, and the circumstances of distribution to determine whether a product is being marketed as a drug regardless of any "not for human consumption" disclaimer ^[8]. If you're researching where products are actually sold and how sourcing works within that gray zone, AOD-9604 for sale and best place to buy AOD-9604 cover that ground directly.

What AOD-9604 dosing protocols show up in the literature and online?

There is no FDA-approved dosing regimen for AOD-9604 peptide, because there's no approved product. What circulates online comes from the discontinued clinical trial protocols and from anecdotal peptide-community practice, not from a labeled prescribing insert. Historically, the clinical development program tested AOD-9604 at daily subcutaneous doses in the range used in Phase IIb obesity trials, generally in the microgram-to-low-milligram range once or twice daily, timed around fasting states to align with the lipolysis rationale. Because the compound never reached approval, there is no FDA-reviewed label specifying an official dose, frequency, or duration, and any numbers you see quoted by a vendor or forum post are not sourced from a regulatory document. If you're trying to understand dosing mechanics, reconstitution, and injection technique that people commonly reference for AOD-9604 peptide, the practical how-to pages are the right next stop: AOD-9604 dosing, how to reconstitute AOD-9604, and AOD-9604 how to inject. Those cover the mechanical side. They can't tell you a dose is proven effective, because the trial record doesn't support that claim regardless of dose used.

Does AOD-9604 show up on a drug test or WADA screening?

This is one of the more settled pieces of the AOD-9604 evidence base, separate from the obesity question entirely. A 2013 study in Drug Testing and Analysis specifically tested whether AOD-9604 interferes with the World Anti-Doping Agency's hGH isoform immunoassay, the test used to detect illicit growth hormone use in athletes, and found that it does not influence that assay ^[9]. That's a narrow but genuinely useful finding: it means AOD-9604 doesn't act as a masking agent for HGH doping via that specific test, and it means the peptide itself is a distinct analytical target rather than something that would confuse an hGH isoform result. Separately, AOD-9604 has been studied as a compound anti-doping labs need to be able to detect in its own right. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis on detecting emerging and non-approved therapeutics in doping controls discusses analytical approaches developed for compounds like AOD-9604 ^[10], and a 2014 review in Expert Review of Proteomics on detecting peptidic drugs in sports doping covers the same territory for peptide analogs generally ^[11]. More recent analytical work has pushed this further. A 2016 paper in the Journal of Separation Science describes a method for screening peptides under 2 kDa (AOD-9604 is a small fragment, well under that threshold) directly from urine using liquid chromatography and ion mobility mass spectrometry ^[12], which is the kind of testing infrastructure now used to catch small peptide doping agents that older immunoassays might miss. If you're an athlete under any testing jurisdiction, the practical takeaway is that AOD-9604 is a known, detectable target in modern anti-doping labs, not an obscure compound that flies under the radar.

What does the current medical literature say about AOD-9604 outside obesity?

Two very recent papers, both from 2026, put AOD-9604 in a different context entirely: orthopaedics and musculoskeletal recovery, not weight loss. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews on therapeutic peptides in orthopaedics discusses AOD-9604 among a set of peptides being explored for applications, challenges, and future directions in that field ^[13]. A second 2026 paper in Sports Medicine reviews the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, again placing AOD-9604 in that broader unapproved-peptide category ^[14]. Both papers are recent enough that they represent where academic attention has shifted: away from AOD-9604 as an obesity drug (a track that stalled out) and toward exploratory interest in cartilage, joint, or soft-tissue applications that early lab work on the HGH fragment suggested might be worth investigating. Neither paper is a clinical trial showing AOD-9604 works for those uses in humans. They're reviews describing the state of an emerging, unapproved category, and both explicitly frame these peptides, AOD-9604 included, as unapproved therapies whose safety and efficacy in this new use case still need real trial data. That's worth knowing if you've seen AOD-9604 marketed for joint or recovery use: the papers exist, but they describe a research direction, not a proven treatment.

What are the honest AOD-9604 peptide benefits, based on the actual data?

Here's the straight answer: based on published human trial data, AOD-9604 has not demonstrated a reliable, placebo-beating fat-loss benefit. That's the central finding to carry away from this topic, and no amount of mechanism-of-action explanation changes it. What AOD-9604 does have is a coherent biological rationale (the isolated lipolytic fragment of HGH), a real Phase II clinical trial history, a clean bill of health regarding not confounding the WADA hGH doping test ^[9], and emerging, very early-stage interest in orthopaedic and musculoskeletal research contexts ^[13][14]. What it does not have is FDA approval for anything, inclusion on the 503A or 503B compounding bulks lists ^[4][5], or a convincing human efficacy trial for weight loss that most people assume exists because of how it's marketed. If you're comparing AOD-9604 peptide benefits against alternatives with a stronger evidence base for fat metabolism or body composition, tesamorelin is the most direct comparison point because it does carry FDA approval, albeit for a narrow indication (reduction of excess abdominal fat in HIV-associated lipodystrophy), and has a real prescribing label backing that specific use. See the AOD-9604 vs tesamorelin comparison for how the trial records actually differ.

How does AOD-9604 compare to GLP-1 drugs or other proven weight-loss options?

It doesn't compare well, if we're being honest about the evidence gap. GLP-1 receptor agonists like semaglutide and tirzepatide have large, published, peer-reviewed randomized controlled trials with weight-loss effects in the double-digit percentage range against placebo, and both have full FDA approval for chronic weight management. AOD-9604's obesity trial record, by contrast, never produced a result strong enough to support an approval filing, and independent literature reviews of the obesity drug pipeline from that era treat it as one candidate among many that did not make it through ^[2]. The fair comparison isn't "AOD-9604 versus nothing." It's AOD-9604 versus the FDA-approved GLP-1 category, versus tesamorelin for its narrow approved indication, and versus doing nothing and just adjusting diet and exercise. In all three of those comparisons, AOD-9604 currently sits at the bottom of the evidence stack. It's cheap and it's easy to find through gray-market research-chemical vendors, but cheap and available is not the same as effective. If your actual goal is fat loss and you're deciding where to put your money and your time, an FDA-approved GLP-1 drug prescribed and monitored by a physician, or a tesamorelin prescription for the specific indication it's approved for, has a materially stronger trial record behind it than AOD-9604 does. That's not a brand opinion, that's what the comparative trial literature shows.

Where does AOD-9604 fit if you still want to try it?

If you've read all of this and still want to research AOD-9604, the responsible path is to go in with correct expectations: this is an unapproved compound with a stalled obesity trial record, not a proven fat-loss therapy. Anyone selling it to you as a guaranteed weight-loss shortcut isn't representing the trial data accurately. AOD-9604 Co reviews provider information and points readers toward a provider-reviewed sourcing route rather than unregulated research-chemical vendors, specifically because purity, dosing accuracy, and legal sourcing all vary enormously across that market. If you're going to look further, start with how sourcing actually works in this space at AOD-9604 for sale, then look at the practical dosing and injection mechanics at AOD-9604 dosing and AOD-9604 how to inject before deciding anything. The bottom line worth repeating: the human obesity trials for AOD-9604 did not produce a weight-loss result that separated convincingly from placebo. Treat every other claim about this peptide, benefits, dosing protocols, joint-repair potential, against that fact.

Frequently asked questions

What is AOD-9604 peptide used for?

AOD-9604 was originally developed as an obesity treatment, designed as a fragment of human growth hormone meant to trigger fat breakdown without HGH's growth effects ^[1]. It went through human trials for that purpose but never gained FDA approval. More recent research has explored it in orthopaedic and musculoskeletal contexts, though that work is early and not a proven treatment ^[13][14].

Does AOD-9604 actually work for weight loss?

The human trial data does not support a clear yes. AOD-9604 went through obesity trials, but published results show weight loss that did not separate convincingly from placebo. It never reached FDA approval for obesity, unlike GLP-1 drugs, which do have strong placebo-controlled trial data behind their approvals.

Is AOD-9604 legal to buy in the US?

AOD-9604 is not FDA-approved and does not appear on the FDA's 503A or 503B lists of bulk substances legally usable in compounded drugs ^[4][5]. It's not classified as a controlled substance, but it exists in a gray zone typically sold as a research chemical, not a legally marketed human drug.

What is the typical AOD-9604 dosing protocol?

There is no FDA-approved dosing label for AOD-9604. Historical clinical trials used daily subcutaneous injections in microgram-to-low-milligram ranges, but since the compound never reached approval, no official dose, frequency, or duration exists. Anything cited online comes from discontinued trial protocols or community anecdote, not a reviewed label.

Will AOD-9604 show up on a drug test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect growth hormone doping ^[9]. However, separate analytical methods, including LC/ion mobility mass spectrometry for small peptides under 2 kDa, have been developed specifically to detect AOD-9604 itself in doping controls ^[12].

How is AOD-9604 different from regular HGH?

AOD-9604 is a synthetic fragment representing just amino acids 176-191 of human growth hormone, the region researchers linked to fat metabolism effects ^[1]. Full HGH has broad growth and metabolic effects across many tissues; AOD-9604 was designed to isolate only the fat-related activity, though human trials never confirmed a strong standalone fat-loss effect.

Is AOD-9604 the same as tesamorelin?

No. Tesamorelin is a growth-hormone-releasing hormone analog with FDA approval for reducing excess abdominal fat in HIV-associated lipodystrophy, a narrow but real approved indication. AOD-9604 is an HGH fragment with no FDA approval for any use and a weaker human trial record. See AOD-9604 vs tesamorelin for the full comparison.

Why did AOD-9604 fail to get FDA approval?

Public trial results and industry pipeline reviews indicate the Phase II obesity trials did not produce weight-loss results strong enough, or clearly separated from placebo enough, to support a successful regulatory filing ^[2]. The company developing it did not advance it to a later-stage approval submission, and no other sponsor has revived an approval push since.

Can AOD-9604 be legally compounded by a pharmacy?

Compounding pharmacies operate under authority granted by 21 U.S.C. 353a ^[7], but they can only use bulk substances on the FDA's 503A or 503B lists. AOD-9604 is absent from both lists as published in 21 CFR 216.23 and 216.24 ^[4][5], meaning legitimate compounding pharmacies in the US are not using it as a listed bulk substance.

Are there any new uses for AOD-9604 being researched now?

Yes. Two 2026 papers, one in JAAOS Global Research & Reviews on peptides in orthopaedics and one in Sports Medicine on peptide therapies for musculoskeletal injuries, both discuss AOD-9604 in the context of joint and soft-tissue research, separate from its original obesity use ^[13][14]. This work is early-stage and does not constitute proven treatment.

What's the difference between AOD-9604 peptide and AOD9604 peptide spelling?

There's no chemical difference. AOD-9604, AOD9604, and "aod 9604 peptide" all refer to the same compound; the variation is just formatting in how vendors and search terms write the name, with or without a hyphen or space.

Is AOD-9604 safe?

There's no large-scale, long-term human safety dataset from a completed approval program, because AOD-9604 never reached that stage. Early trials reportedly did not show the growth or insulin-resistance side effects associated with full HGH, but without an approved label or postmarket surveillance, safety data remains limited compared to approved drugs like tesamorelin or GLP-1 agonists.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Describes AOD-9604's rationale as an HGH fragment designed to stimulate lipolysis and inhibit lipogenesis without HGH's growth or blood-sugar effects.
2. PubMed, Current Opinion in Investigational Drugs (2006): Reviews the obesity drug clinical development pipeline of that era, situating AOD-9604 among candidates being tracked.
3. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product for any indication.
4. eCFR, 21 CFR 216.23, the 503A Bulks List: AOD-9604 is not included on the FDA's 503A list of bulk substances approved for compounding.
5. eCFR, 21 CFR 216.24, the 503B Bulks List: AOD-9604 is not included on the FDA's 503B list of bulk substances approved for outsourcing facility compounding.
6. FDA, bulk drug substances nominated for use in compounding: AOD-9604 does not appear on FDA's current list of nominated bulk substances evaluated for compounding use.
7. Cornell Law, 21 U.S.C. 353a: Establishes the statutory authority under which pharmacy compounding of drug substances is legally permitted.
8. eCFR, 21 CFR 201.128, meaning of intended uses: Defines how FDA determines a product's intended use based on labeling and advertising regardless of disclaimers.
9. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect growth hormone doping.
10. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Discusses analytical approaches developed for detecting emerging, non-approved therapeutics including compounds like AOD-9604 in doping controls.
11. PubMed, Expert Review of Proteomics (2014): Reviews methods for detecting peptidic drugs and analogs, including AOD-9604-type compounds, in sports doping controls.
12. PubMed, Journal of Separation Science (2016): Describes an LC and ion mobility mass spectrometry method for screening peptides under 2 kDa, the size class AOD-9604 falls into, directly from urine.
13. PubMed, JAAOS Global Research & Reviews (2026): Discusses AOD-9604 among therapeutic peptides being explored in orthopaedic applications, challenges, and future research directions.
14. PubMed, Sports Medicine (2026): Reviews safety and efficacy of approved and unapproved peptide therapies, including AOD-9604, for musculoskeletal injuries and athletic performance.